R. Cuffe

发表

HIV prevention trial design in an era of effective pre-exposure prophylaxis

R. D. Meyer, D. Glidden, D. Dunn, 2017, HIV clinical trials.

Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir

J. Roger, Cunshan Wang, R. Cuffe, 2015, HIV clinical trials.

Informing the selection of futility stopping thresholds: case study from a late‐phase clinical trial

A. Lieftucht, S. Hughes, R. Cuffe, 2009, Pharmaceutical statistics.

A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.

M. Watson, R. Cuffe, P. Wannamaker, 2009, AIDS patient care and STDs.

When is a seamless study desirable? Case studies from different pharmaceutical sponsors

Andrew Stone, David Lawrence, Marc Vandemeulebroecke, 2014, Pharmaceutical statistics.

48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis

J. Stephens, R. R. Camejo, S. Snedecor, 2014, PloS one.

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

S. Walmsley, F. Raffi, A. Rachlis, 2015, AIDS.

The statistician's role in the prevention of missing data

Robert L Cuffe, Julia Harris, S. Hughes, 2012, Pharmaceutical statistics.

Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572)

F. Deanda, Joseph H Horton, A. Sato, 2013, Antimicrobial Agents and Chemotherapy.

Informing the selection of futility stopping thresholds: case study from a late‐phase clinical trial

A. Lieftucht, S. Hughes, R. Cuffe, 2009, Pharmaceutical statistics.

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

C. Katlama, A. Lazzarin, P. Morlat, 2010, Journal of the International AIDS Society.